CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Ibritumomab tiuxetan|
|Indication||Non-Hodgkin’s Lymphoma (NHL)|
|Review Status||Not Filed|
|Manufacturer||Servier Canada Inc.|
|Clarification||CADTH is unable to recommend reimbursement of the relevant product because a submission to CADTH was not filed by the manufacturer.|
|Last Updated||June 17, 2019|